PL2041093T3 - Pochodne piperazynylowe użyteczne w leczeniu zaburzeń, którym pośredniczy receptor GPR38 - Google Patents

Pochodne piperazynylowe użyteczne w leczeniu zaburzeń, którym pośredniczy receptor GPR38

Info

Publication number
PL2041093T3
PL2041093T3 PL07765616T PL07765616T PL2041093T3 PL 2041093 T3 PL2041093 T3 PL 2041093T3 PL 07765616 T PL07765616 T PL 07765616T PL 07765616 T PL07765616 T PL 07765616T PL 2041093 T3 PL2041093 T3 PL 2041093T3
Authority
PL
Poland
Prior art keywords
treatment
mediated diseases
receptor mediated
derivatives useful
gpr38 receptor
Prior art date
Application number
PL07765616T
Other languages
English (en)
Inventor
Darren Jason Mitchell
Jonathan Thomas Seal
Mervyn Thompson
Susan Marie Westaway
Samantha Louisa Brown
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38476358&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2041093(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0612844A external-priority patent/GB0612844D0/en
Priority claimed from GB0711525A external-priority patent/GB0711525D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PL2041093T3 publication Critical patent/PL2041093T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
PL07765616T 2006-06-28 2007-06-26 Pochodne piperazynylowe użyteczne w leczeniu zaburzeń, którym pośredniczy receptor GPR38 PL2041093T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0612844A GB0612844D0 (en) 2006-06-28 2006-06-28 Compounds
GB0711525A GB0711525D0 (en) 2007-06-14 2007-06-14 Compounds
PCT/EP2007/056342 WO2008000729A1 (en) 2006-06-28 2007-06-26 Piperazinyl derivatives useful in the treatment of gpr38 receptor mediated diseases
EP07765616A EP2041093B1 (en) 2006-06-28 2007-06-26 Piperazinyl derivatives useful in the treatment of gpr38 receptor mediated diseases

Publications (1)

Publication Number Publication Date
PL2041093T3 true PL2041093T3 (pl) 2010-09-30

Family

ID=38476358

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07765616T PL2041093T3 (pl) 2006-06-28 2007-06-26 Pochodne piperazynylowe użyteczne w leczeniu zaburzeń, którym pośredniczy receptor GPR38

Country Status (30)

Country Link
US (2) US7700599B2 (pl)
EP (1) EP2041093B1 (pl)
JP (1) JP5028484B2 (pl)
KR (1) KR20090031688A (pl)
AR (1) AR061656A1 (pl)
AT (1) ATE465150T1 (pl)
AU (1) AU2007263712B2 (pl)
BR (1) BRPI0713443A2 (pl)
CA (1) CA2655540A1 (pl)
CR (1) CR10497A (pl)
CY (1) CY1110190T1 (pl)
DE (1) DE602007006019D1 (pl)
DK (1) DK2041093T3 (pl)
EA (1) EA015820B1 (pl)
ES (1) ES2344484T3 (pl)
HK (1) HK1127608A1 (pl)
HR (1) HRP20100284T1 (pl)
IL (1) IL195900A0 (pl)
JO (1) JO2645B1 (pl)
MA (1) MA30539B1 (pl)
MX (1) MX2009000110A (pl)
MY (1) MY147677A (pl)
NO (1) NO20090266L (pl)
NZ (1) NZ573450A (pl)
PE (1) PE20080345A1 (pl)
PL (1) PL2041093T3 (pl)
PT (1) PT2041093E (pl)
SI (1) SI2041093T1 (pl)
TW (1) TWI391386B (pl)
WO (1) WO2008000729A1 (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0611907D0 (en) 2006-06-15 2006-07-26 Glaxo Group Ltd Compounds
US8536182B2 (en) * 2005-07-26 2013-09-17 Glaxo Group Limited Benzylpiperazine derivatives and their medical use
GB0524814D0 (en) * 2005-12-05 2006-01-11 Glaxo Group Ltd Compounds
JP5028484B2 (ja) * 2006-06-28 2012-09-19 グラクソ グループ リミテッド Ｇｐｒ３８受容体媒介疾患の治療に有用なピペラジニル誘導体
GB0723317D0 (en) 2007-11-28 2008-01-09 Glaxo Group Ltd Compounds
CA2750699C (en) * 2009-02-27 2015-12-29 Raqualia Pharma Inc. Oxyindole derivatives with motilin receptor agonistic activity
US9452980B2 (en) 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
JP2013518085A (ja) 2010-02-01 2013-05-20 ノバルティス アーゲー ＣＲＦ−１受容体アンタゴニストとしてのピラゾロ［５，１ｂ］オキサゾール誘導体
WO2011092293A2 (en) 2010-02-01 2011-08-04 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
ES2527849T3 (es) 2010-02-02 2015-01-30 Novartis Ag Derivados de ciclohexilamida como antagonistas del receptor de CRF
NZ609596A (en) 2010-09-27 2013-12-20 Daiichi Sankyo Co Ltd Cyclohexane derivative compound
US9321727B2 (en) * 2011-06-10 2016-04-26 Hoffmann-La Roche Inc. Pyridine derivatives as agonists of the CB2 receptor
WO2017157873A1 (en) 2016-03-17 2017-09-21 F. Hoffmann-La Roche Ag 5-ethyl-4-methyl-pyrazole-3-carboxamide derivative having activity as agonist of taar
MX2023003446A (es) * 2020-09-25 2023-06-22 Shanghai Meiyue Biotech Dev Co Ltd Compuesto de pirimidina carboxamida y aplicación del mismo.

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5385912A (en) * 1991-03-08 1995-01-31 Rhone-Poulenc Rorer Pharmaceuticals Inc. Multicyclic tertiary amine polyaromatic squalene synthase inhibitors
TW355711B (en) 1992-11-04 1999-04-11 Chugai Pharmaceutical Co Ltd Erythromycin derivatives
JPH06211886A (ja) 1992-11-04 1994-08-02 Chugai Pharmaceut Co Ltd エリスロマイシン誘導体
US5593994A (en) * 1994-09-29 1997-01-14 The Dupont Merck Pharmaceutical Company Prostaglandin synthase inhibitors
JP3901239B2 (ja) 1996-03-13 2007-04-04 大正製薬株式会社 アリールアルカン誘導体
US5965578A (en) * 1996-04-03 1999-10-12 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
DE19644195A1 (de) 1996-10-24 1998-04-30 Solvay Pharm Gmbh 10,13,15-Trioxatricyclo[9.2.1.1.·9·.·6·]-pentadecanon-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US6100239A (en) * 1996-11-26 2000-08-08 Chugai Seiyaku Kabushiki Kaisha 13-membered ring macrolide compound, medicine containing the same, and process for producing the same
US6060491A (en) * 1997-06-19 2000-05-09 Dupont Pharmaceuticals 6-membered aromatics as factor Xa inhibitors
US5972939A (en) * 1997-10-28 1999-10-26 Ortho-Mcneil Pharmaceutical, Inc. Cyclopentene derivatives useful as antagonists of the motilin receptor
US6165985A (en) 1998-02-13 2000-12-26 Solvay Pharmaceuticals Gmbh 11-acetyl-12,13-dioxabicyclo[8.2.1]-tridecenone derivatives, processes for their preparation and pharmaceutical compositions comprising them
DE19805822B4 (de) 1998-02-13 2009-02-05 Solvay Pharmaceuticals Gmbh 11-Acetyl-12,13-dioxabicyclo[8.2.1]tridecenon-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
GB9804734D0 (en) * 1998-03-05 1998-04-29 Pfizer Ltd Compounds
IL144910A0 (en) * 1999-04-15 2002-06-30 Bristol Myers Squibb Co Cyclic compounds and pharmaceutical compositions containing the same
US20020010184A1 (en) * 2000-02-18 2002-01-24 Dinsmore Christopher J. Inhibitors of prenyl-protein transferase
US20020052380A1 (en) * 2000-02-18 2002-05-02 Dinsmore Christopher J. Inhibitors of prenyl-protein transferase
AU2001247357A1 (en) * 2000-03-13 2001-09-24 Ortho-Mcneil Pharmaceutical, Inc. Novel cyclobutene derivatives useful as antagonists of the motilin receptor
US6423714B2 (en) * 2000-03-13 2002-07-23 Ortho Mcneil-Pharmaceutical, Inc.. Cyclohexene derivatives useful as antagonists of the motilin receptor
WO2001068620A1 (en) * 2000-03-13 2001-09-20 Ortho-Mcneil Pharmaceutical, Inc. Novel cyclopentene derivatives useful as antagonists of the motilin receptor
US6511980B2 (en) * 2000-05-05 2003-01-28 Ortho Mcneil Pharmaceutical, Inc. Substituted diamine derivatives useful as motilin antagonists
GB0013378D0 (en) * 2000-06-01 2000-07-26 Glaxo Group Ltd Use of therapeutic benzamide derivatives
US7105682B2 (en) * 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
US6878714B2 (en) * 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
US7102009B2 (en) 2001-01-12 2006-09-05 Amgen Inc. Substituted amine derivatives and methods of use
EP1392679B1 (de) 2001-05-10 2005-11-02 Solvay Pharmaceuticals GmbH Neue 1-amidomethylcarbonyl-piperidinderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US6977264B2 (en) * 2001-07-25 2005-12-20 Amgen Inc. Substituted piperidines and methods of use
GB0129013D0 (en) * 2001-12-04 2002-01-23 Glaxo Group Ltd Compounds
GB0129015D0 (en) * 2001-12-04 2002-01-23 Glaxo Group Ltd Compounds
SE0203302D0 (sv) * 2002-11-07 2002-11-07 Astrazeneca Ab Novel Compounds
US7223788B2 (en) * 2003-02-14 2007-05-29 Sanofi-Aventis Deutschland Gmbh Substituted N-aryl heterocycles, process for their preparation and their use as medicaments
US7262195B2 (en) 2003-09-17 2007-08-28 Bristol-Myers Squibb Company Compounds useful as motilin agonists and method
US7338954B2 (en) 2003-09-17 2008-03-04 Bristol-Myers Squibb Company Compounds useful as motilin agonists and method
CA2540826A1 (en) * 2003-10-01 2005-04-14 The Procter & Gamble Company Melanin concentrating hormone antagonists
JPWO2005063720A1 (ja) * 2003-12-25 2007-07-19 日本新薬株式会社 アミド誘導体及び医薬
WO2005077373A2 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Treatment of gastro-esophageal reflux disease (gerd)
WO2005077368A2 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Treatment of gastro-esophageal reflux disease (gerd)
WO2005077345A1 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Compounds for the treatment of gastro-esophageal reflux disease
US20050277629A1 (en) * 2004-03-18 2005-12-15 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies (Lansbury)
US20070293539A1 (en) * 2004-03-18 2007-12-20 Lansbury Peter T Methods for the treatment of synucleinopathies
SE0401345D0 (sv) 2004-05-25 2004-05-25 Astrazeneca Ab Therapeutic compounds: Pyridine as scaffold
GB0611907D0 (en) 2006-06-15 2006-07-26 Glaxo Group Ltd Compounds
JP2009501199A (ja) 2005-07-12 2009-01-15 グラクソ グループ リミテッド Ｇｐｒ３８アゴニストとしてのピペラジンヘテロアリール誘導体
US8536182B2 (en) 2005-07-26 2013-09-17 Glaxo Group Limited Benzylpiperazine derivatives and their medical use
JP5028484B2 (ja) * 2006-06-28 2012-09-19 グラクソ グループ リミテッド Ｇｐｒ３８受容体媒介疾患の治療に有用なピペラジニル誘導体

Also Published As

Publication number Publication date
JO2645B1 (en) 2012-06-17
CY1110190T1 (el) 2015-01-14
AR061656A1 (es) 2008-09-10
DE602007006019D1 (de) 2010-06-02
TWI391386B (zh) 2013-04-01
TW200817352A (en) 2008-04-16
NO20090266L (no) 2009-03-17
DK2041093T3 (da) 2010-08-02
EP2041093B1 (en) 2010-04-21
JP2009541432A (ja) 2009-11-26
JP5028484B2 (ja) 2012-09-19
KR20090031688A (ko) 2009-03-27
US7700599B2 (en) 2010-04-20
AU2007263712B2 (en) 2012-08-30
MA30539B1 (fr) 2009-06-01
IL195900A0 (en) 2009-09-01
US8853218B2 (en) 2014-10-07
CR10497A (es) 2009-03-20
PE20080345A1 (es) 2008-05-29
MX2009000110A (es) 2009-01-23
ES2344484T3 (es) 2010-08-27
HK1127608A1 (en) 2009-10-02
MY147677A (en) 2012-12-31
EA015820B1 (ru) 2011-12-30
CA2655540A1 (en) 2008-01-03
US20090192160A1 (en) 2009-07-30
EA200970065A1 (ru) 2009-06-30
ATE465150T1 (de) 2010-05-15
PT2041093E (pt) 2010-06-28
WO2008000729A1 (en) 2008-01-03
US20080027065A1 (en) 2008-01-31
SI2041093T1 (sl) 2010-07-30
BRPI0713443A2 (pt) 2012-03-06
AU2007263712A1 (en) 2008-01-03
EP2041093A1 (en) 2009-04-01
NZ573450A (en) 2011-11-25
HRP20100284T1 (hr) 2010-06-30

Similar Documents

Publication Publication Date Title
IL195900A0 (en) Piperazinyl derivatives useful in the treatment of gpr38 receptor mediated diseases
ZA201000075B (en) Purin derivatives for use in the treatment of fab-related diseases
IL193230A (en) Use of benzoxoborol derivatives in the preparation of drugs for the treatment of inflammatory diseases
HK1153926A1 (en) Purin derivatives for use in the treatment of fab-related diseases fab-
HK1142908A1 (en) Pyrazinone derivatives and their use in the treatment of lung diseases
IL189578A0 (en) Pyridine derivatives and their use in the treatment of psychotic disorders
IL184934A0 (en) 4-oxoquinazoline-3-yl-benzamide derivatives for the treatment of cytokine diseases
IL195906A0 (en) Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
ZA201004134B (en) 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressine-dependent diseases
IL216967B (en) The history of 17-hydroxy-17-pentafluoroethyl-astra-9,4 (10)-diene-11-aryl and their use for the treatment of diseases
HK1203482A1 (en) Phenoxypyridinylamide derivatives and their use in the treatment of pde4 mediated disease states pde4
EP2148667A4 (en) USE OF CYCLOHEXANHEXOL DERIVATIVES IN THE TREATMENT OF EYE DISEASES
IL196745A (en) Idabanon for use in providing mucosal pathways to treat disease
EP2217238A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF DISEASES RELATED TO PROTEINURIA
ZA201108106B (en) Use of phthalimide derivatives in the treatment of diseases
HK1134032A1 (en) New combination for use in the treatment of inflammatory disorders
GB0620695D0 (en) Composition and methods for the treatment of nurdegenerative disease
GB0710277D0 (en) Use of antivirals in the treatment of medical disorders
ZA200810373B (en) Piperazinyl derivatives useful in the treatment of GPR38 receptor mediated diseases
IL204957A (en) Derivatives of 3 - (aminoalkoxyimino) - androstane and androsten
ZA200801548B (en) Pyridine derivatives and their use in the treatment of psychotic disorders
ZA200909073B (en) Pyrazinone derivatives and their use in the treatment of lung diseases
HK1125634A1 (en) Pharmaceutical for use in the treatment of ureterolithiasis
IL202502A0 (en) Agents for the treatment of inflammatory diseases and methods of using same
ZA200904249B (en) New combination for use in the treatment of inflammatory disorders